Crinetics Pharmaceuticals Inc Total Liabilities
Crinetics Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Crinetics Pharmaceuticals Inc (CRNX) has total liabilities worth $129.92 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Crinetics Pharmaceuticals Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Crinetics Pharmaceuticals Inc (2016–2025)
Total liabilities of Crinetics Pharmaceuticals Inc from 2016 to 2025. This chart illustrates how Crinetics Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Check Crinetics Pharmaceuticals Inc (CRNX) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Crinetics Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Crinetics Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hella KGaA Hueck & Co
XETRA:HLE
|
Germany | €4.17 Billion |
|
SpareBank 1 Sør-Norge ASA
OL:SB1NO
|
Norway | Nkr491.18 Billion |
|
Banca Transilvania S.A.
RO:TLV
|
Romania | RON201.12 Billion |
|
Sirius XM Holding Inc
NASDAQ:SIRI
|
USA | $15.42 Billion |
|
Baloise Holding AG
SW:BALN
|
Switzerland | CHF75.34 Billion |
|
Komercni Banka A.S.
PR:KOMB
|
Czech Republic | Kč1.68 Trillion |
|
Kymera Therapeutics Inc
NASDAQ:KYMR
|
USA | $139.85 Million |
|
Ningbo Deye Technology Co Ltd
SHG:605117
|
China | CN¥9.19 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down Crinetics Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Crinetics Pharmaceuticals Inc asset portfolio.
Liquidity & Leverage Metrics
Crinetics Pharmaceuticals Inc Total Liabilities Ratios Explained
Crinetics Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 15.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Crinetics Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Crinetics Pharmaceuticals Inc (2016–2025)
The table below shows the annual total liabilities of Crinetics Pharmaceuticals Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $143.41 Million | +30.63% |
| 2024-12-31 | $109.79 Million | +14.07% |
| 2023-12-31 | $96.25 Million | +168.49% |
| 2022-12-31 | $35.85 Million | +87.97% |
| 2021-12-31 | $19.07 Million | +31.29% |
| 2020-12-31 | $14.53 Million | +9.73% |
| 2019-12-31 | $13.24 Million | +18.30% |
| 2018-12-31 | $11.19 Million | -63.46% |
| 2017-12-31 | $30.62 Million | +62.85% |
| 2016-12-31 | $18.80 Million | -- |
About Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acrome… Read more